Navigation Links
Clinical trial data: Safety/efficacy of concomitant formoterol fumarate/tiotropium treating COPD
Date:10/24/2007

Napa, CA (October 24, 2007) Data presented today at CHEST 2007, the annual scientific assembly of the American College of Chest Physicians (ACCP), demonstrate concomitant use of nebulized formoterol fumarate and tiotropium provided improved bronchodilation over tiotropium monotherapy and was well-tolerated in this clinical study. The only commercially available version of nebulized formoterol fumarate is Perforomist Inhalation Solution, which is indicated for long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD).

Formoterol fumarate is a rapid and long-acting beta2-agonist (LABA) that has been previously available in the U.S. in a dry powder formulation and has twenty years of worldwide experience. Perforomist Inhalation Solution is the first and only FDA-approved nebulized form of this molecule. Nebulizers convert liquid medication into a mist that patients inhale through a mouthpiece or face mask.

Results presented were from Safety and Efficacy of Concomitant Treatment with Nebulized Formoterol and Tiotropium in COPD, a randomized, placebo-controlled Phase IIIb trial. The trial demonstrated that concomitant therapy with twice-daily nebulized formoterol fumarate (FFIS) and once-daily tiotropium provided patients with statistically significant and clinically relevant improvements in bronchodilation over treatment with tiotropium alone. In this six-week study, patients receiving concomitant therapy with nebulized FFIS and tiotropium experienced fewer adverse events or COPD exacerbations than patients receiving placebo or tiotropium monotherapy.

According to Donald P. Tashkin, MD, FACP, FCCP, Professor of Medicine, David Geffen School of Medicine at the University of California at Los Angeles and the lead clinical investigator, For the patients in this study, adjunctive use of nebulized formoterol fumarate and tiotropium showed statistically significant improvements in lung function by improving bronchodilation over use of tiotropium alone. For physicians, Perforomist Inhalation Solution and commonly prescribed long-acting anticholinergics such as tiotropium offers a new and valuable treatment option for COPD patients with moderate to severe manifestations of the disease.

Christy Taylor, Chief Operating Officer at Dey, L.P., commented, At DEY, we specialize in developing effective new treatments for serious and complex respiratory diseases, and it is gratifying that the newest addition to our franchise, Perforomist Inhalation Solution, offers physicians additional prescribing flexibility. For over a decade, Dey, L.P. has been the U.S. leader in sales of nebulized respiratory medication. We thank Dr. Tashkin and the other members of the research team for their assessment of how Perforomist Inhalation Solution may be used concomitantly with tiotropium for improved clinical effect for COPD patients.

For those attending CHEST 2007, the presentation is available as follows:

Poster viewing: Session ID 902 - COPD Treatment II
Wednesday, October 24, 2007, 12:30 2:00 PM
Convention Center, Exhibit Hall, McCormick Place, Lakeside Center, Chicago.

Poster # 251: Safety and Efficacy of Concomitant Treatment with Nebulized Formoterol and Tiotropium in COPD


'/>"/>

Contact: Amy Techtmann
amy.techtmann@fkhealth.com
617-761-6784
Feinstein Kean Healthcare
Source:Eurekalert

Related medicine news :

1. How do patients benefit of clinical trials
2. Magnetic resonance angiography in clinical medicine
3. Clinical trials need to be more frank
4. AEternas acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy
5. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
6. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
7. Clinical Comparisons Between ADHD Drugs Are Less
8. Outsourcing clinical trials to India
9. Erectile dysfunction: an early warning sign of clinically silent coronary artery disease?
10. India to maintain Public domain Registry database of clinical trials conducted in India.
11. A Novel System For Clinical Banking Of Umbilical Cord Blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... T.E.N., a technology and information ... ISE Southeast Awards 2016. Finalists and winners of the ISE® Awards for both ... and Awards Gala on March 15, 2016 at the Westin Peachtree Plaza, Atlanta. ...
(Date:2/12/2016)... NC (PRWEB) , ... February 12, 2016 , ... AssureVest ... surrounding areas, is initiating a charity drive that will raise funds earmarked to purchase ... John C. Tayloe Elementary School. , “My school is in a low-income area and ...
(Date:2/12/2016)... CA (PRWEB) , ... February 12, 2016 , ... Donor ... in northern California and Nevada, announced a partnership with San Ramon Regional Medical Center. ... to the hospital’s facilities as a way to accommodate a more certain time frame ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... about foods choices that promote eye health. These articles generally list between five ... and health advocate Sharon Kleyne endorses every one of these lists and believes ...
(Date:2/12/2016)... ... , ... Healthcare careers in the medical laboratory, nursing, and in the imaging ... healthcare staffing leader Aureus Medical Group during the month of January. Aureus Medical specializes ... positions and in travel and direct hire opportunities in other allied health fields. , ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... , Feb. 11, 2016  Kindred Biosciences, Inc. (NASDAQ: ... and improving the lives of pets, today announced the ... the New Animal Drug Application (NADA) for Zimeta™ (dipyrone ... study (KB0120) of Zimeta for the control of pyrexia ... --> --> The ...
(Date:2/11/2016)... 11, 2016   Health 2.0 , the premiere ... technologies, announced today " 10 Year Global Retrospective ", ... over the past ten years.   ... Health 2.0 has served as the preeminent thought-leader in ... thousands of technologies, companies, innovators, and patient-activists through an ...
(Date:2/11/2016)... 2016  MiMedx Group, Inc. (NASDAQ: MDXG ), ... and other birth tissues, human skin and bone, and ... advanced products and therapies, announced today that it will ... Conference in New York , NY.  ... J. Senken , Chief Financial Officer and Chris ...
Breaking Medicine Technology: